Association of a novel in-frame deletion mutation of the MYH9 gene with end-stage renal failure: Case report and review of the literature

Clinical Nephrology

Volumn 80, Issue 3, 2013, Pages 218-222

  Ishida, Mami ^a   Mori, Yasukiyo ^a   Ota, Noriyoshi ^a   Inaba, Toru ^a   Kunishima, Shinji ^b  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

Author keywords

Chronic kidney disease; MYH9 disorders; Nonmuscle myosin heavy chain IIA; Peritoneal dialysis

Indexed keywords

ADULT; ARTICLE; CASE REPORT; CATHETERIZATION; GENE; GENE DELETION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; KIDNEY FAILURE; LEG EDEMA; MALE; MYH9 GENE; NUCLEOTIDE SEQUENCE; PERCEPTION DEAFNESS; PERITONEAL DIALYSIS; PHENOTYPE; PROTEINURIA; URINALYSIS;

ADULT; DNA MUTATIONAL ANALYSIS; EXONS; GENETIC PREDISPOSITION TO DISEASE; HEARING LOSS, SENSORINEURAL; HUMANS; INCLUSION BODIES; KIDNEY FAILURE, CHRONIC; LEUKOCYTES; MALE; MOLECULAR MOTOR PROTEINS; MYOSIN HEAVY CHAINS; PERITONEAL DIALYSIS; PHENOTYPE; SEQUENCE DELETION; THROMBOCYTOPENIA;

EID: 84884525881     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN107237     Document Type: Article

References (16)

1. Kunishima S, Saito H. Advances in the understanding of MYH9 disorders. Curr Opin Hematol. 2010; 17: 405-410. doi:10.1097/MOH.0 b01 3e3 28 33c069c PubMed
2. Kunishima S, Kojima T, Tanaka T, Kamiya T, Ozawa K, Nakamura Y, Saito H. Mapping of a gene for May-Hegglin anomaly to chromosome 22q. Hum Genet. 1999; 105: 379-383. doi:10.1007/ s004390051119 PubMed
3. Kelley MJ, Jawien W, Lin A, Hoffmeister K, Pugh EW, Doheny KF, Korczak JF. Autosomal dominant macrothrombocytopenia with leukocyte inclusions (May-Hegglin anomaly) is linked to chromosome 22q12-13. Hum Genet. 2000; 106: 557-564. doi:10.1007/s004390050025 PubMed
4. Martignetti JA, Heath KE, Harris J, Bizzaro N, Savoia A, Balduini CL, Desnick RJ. The gene for May-Hegglin anomaly localizes to a < 1-Mb region on chromosome 22q12.3-13.1. Am J Hum Genet. 2000; 66: 1449-1454. doi:10.1086/302873 PubMed
5. Toren A, Rozenfeld-Granot G, Rocca B, Epstein CJ, Amariglio N, Laghi F, Landolfi R, Brok-Simoni F, Carlsson LE, Rechavi G, Greinacher A. Autosomal- dominant giant platelet syndromes: a hint of the same genetic defect as in Fechtner syndrome owing to a similar genetic linkage to chromosome 22q11-13. Blood. 2000; 96: 3447-3451. PubMed
6. Peterson LC, Rao KV, Crosson JT, White JG. Fechtner syndrome-a variant of Alport's syndrome with leukocyte inclusions and macrothrombocytopenia. Blood. 1985; 65: 397-406. PubMed
7. Arrondel C, Vodovar N, Knebelmann B, Grünfeld JP, Gubler MC, Antignac C, Heidet L. Expression of the nonmuscle myosin heavy chain IIA in the human kidney and screening for MYH9 mutations in Epstein and Fechtner syndromes. J Am Soc Nephrol. 2002; 13: 65-74. PubMed
8. Ghiggeri GM, Caridi G, Magrini U, Sessa A, Savoia A, Seri M, Pecci A, Romagnoli R, Gangarossa S, Noris P, Sartore S, Necchi V, Ravazzolo R, Balduini CL. Genetics, clinical and pathologi cal features of glomerulonephritis associated with mutations of nonmuscle myosin IIA (Fechtner syndrome). Am J Kidney Dis. 2003; 41: 95-104. doi:10.1053/ajkd.2003.50028 PubMed
9. Singh N, Nainani N, Arora P, Venuto RC. CKD in MYH9-related disorders. Am J Kidney Dis. 2009; 54: 732-740. doi:10.1053/j.ajkd.2009.06.023 PubMed
10. Seri M, Pecci A, Di Bari F, Cusano R, Savino M, Panza E, Nigro A, Noris P, Gangarossa S, Rocca B, Gresele P, Bizzaro N, Malatesta P, Koivisto PA, Longo I, Musso R, Pecoraro C, Iolascon A, Magrini U, Rodriguez Soriano J, et al. MYH9- related disease: May-Hegglin anomaly, Sebastian syndrome, Fechtner syndrome, and Epstein syndrome are not distinct entities but represent a variable expression of a single illness. Medicine (Baltimore). 2003; 82: 203-215. doi:10.1097/01. md.0000076006.64510.5c PubMed
11. Kunishima S, Matsushita T, Shiratsuchi M, Ikuta T, Nishimura J, Hamaguchi M, Naoe T, Saito H. Detection of unique neutrophil non-muscle myosin heavy chain-A localization by immunofluorescence analysis in MYH9 disorder presented with macrothrombocytopenia without leukocyte inclusions and deafness. Eur J Haematol. 2005; 74: 1-5. doi:10.1111/j.1600-0609.2004.00328.x PubMed
12. Kunishima S, Matsushita T, Hamaguchi M, Saito H. Identification and characterization of the first large deletion of the MYH9 gene associated with MYH9 disorders. Eur J Haematol. 2008; 80: 540-544. doi:10.1111/j.1600-0609.2008.01046.x PubMed
13. Miyazaki K, Kunishima S, Fujii W, Higashihara M. Identification of three in-frame deletion mutations in MYH9 disorders suggesting an important hot spot for small rearrangements in MYH9 exon 24. Eur J Haematol. 2009; 83: 230-234. doi:10.1 1 11/j.1600-0609.2009.01274.x PubMed
14. Kopp JB, Winkler CA, Nelson GW. MYH9 genetic variants associated with glomerular disease: what is the role for genetic testing? Semin Nephrol. 2010; 30: 409-417. doi:10.1016/j.semnephrol.2 01 0.06.007 PubMed
15. Sekine T, Konno M, Sasaki S, Moritani S, Miura T, Wong WS, Nishio H, Nishiguchi T, Ohuchi MY, Tsuchiya S, Matsuyama T, Kanegane H, Ida K, Miura K, Harita Y, Hattori M, Horita S, Igarashi T, Saito H, Kunishima S. Patients with Epstein- Fechtner syndromes owing to MYH9 R702 mutations develop progressive proteinuric renal disease. Kidney Int. 2010;78:207-214.doi:10.1038/ ki.2010.21 PubMed
16. De Rocco D, Pujol-Moix N, Pecci A, Faletra F, Bozzi V, Balduini CL, Savoia A. Identification of the first duplication in MYH9-related disease: a hot spot for unequal crossing-over within exon 24 of the MYH9 gene. Eur J Med Genet. 2009; 52: 191-194. doi:10.1016/j.ejmg.2009.01.006 PubMed